5a8e: Difference between revisions
No edit summary |
No edit summary |
||
Line 1: | Line 1: | ||
==thermostabilised beta1-adrenoceptor with rationally designed inverse agonist 7-methylcyanopindolol bound== | ==thermostabilised beta1-adrenoceptor with rationally designed inverse agonist 7-methylcyanopindolol bound== | ||
<StructureSection load='5a8e' size='340' side='right' caption='[[5a8e]], [[Resolution|resolution]] 2.40Å' scene=''> | <StructureSection load='5a8e' size='340' side='right' caption='[[5a8e]], [[Resolution|resolution]] 2.40Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>[[5a8e]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Melga Melga]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5A8E OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5A8E FirstGlance]. <br> | <table><tr><td colspan='2'>[[5a8e]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Melga Melga]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5A8E OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5A8E FirstGlance]. <br> | ||
Line 18: | Line 18: | ||
</div> | </div> | ||
<div class="pdbe-citations 5a8e" style="background-color:#fffaf0;"></div> | <div class="pdbe-citations 5a8e" style="background-color:#fffaf0;"></div> | ||
==See Also== | |||
*[[Adrenergic receptor 3D structures|Adrenergic receptor 3D structures]] | |||
== References == | == References == | ||
<references/> | <references/> |
Revision as of 11:13, 6 March 2019
thermostabilised beta1-adrenoceptor with rationally designed inverse agonist 7-methylcyanopindolol boundthermostabilised beta1-adrenoceptor with rationally designed inverse agonist 7-methylcyanopindolol bound
Structural highlights
Function[ADRB1_MELGA] Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately equal affinity. Publication Abstract from PubMedComparisons between structures of the lower case beta1-adrenergic receptor (beta1AR) bound to either agonists, partial agonists or weak partial agonists led to the proposal that rotamer changes of Ser5.46, coupled to a contraction of the binding pocket, are sufficient to increase the probability of receptor activation. Cyanopindolol is a weak partial agonist of beta1AR and, based on the hypothesis above, we predicted that the addition of a methyl group to form 7-methylcyanopindolol would reduce dramatically its efficacy. An eight-step synthesis of 7-methylcyanopindolol was developed and its pharmacology analysed. 7-Methylcyanopindolol bound with similar affinity to cyanopindolol to both beta1AR and beta2AR. As predicted, the efficacy of 7-methylcyanopindolol was dramatically reduced compared to cyanopindolol, acting as a very weak partial of turkey beta1AR and an inverse agonist of human beta2AR. The structure of 7-methylcyanopindolol-bound beta1AR was determined to 2.4 A resolution and found to be virtually identical to the structure of cyanopindolol-bound beta1AR. The major differences in the orthosteric binding pocket are that it has expanded by 0.3 A in 7-methylcyanopoindol-bound beta1AR and the hydroxyl group of Ser5.46 is positioned 0.8 A further from the ligand with respect to the position of the Ser5.46 side chain in cyanopindolol-bound beta1AR. Thus the molecular basis for the reduction in efficacy of 7-methylcyanopindolol compared to cyanopindolol may be regarded as the opposite of the mechanism proposed for the increase in efficacy of agonists compared to antagonists. Pharmacological Analysis and Structure Determination of 7-Methylcyanopindolol-Bound beta1-Adrenergic Receptor.,Sato T, Baker J, Warne T, Brown G, Leslie A, Congreve M, Tate C Mol Pharmacol. 2015 Sep 18. pii: mol.115.101030. PMID:26385885[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See AlsoReferences
|
|